公开(公告)号：US20200077918A1

公开(公告)日：2020-03-12

申请号：US16127816

申请日：2018-09-11

Applicant: ICM - INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE ,  INSERM ,  CNRS ,  APHP ,  Sorbonne-Université

Inventor： Federico RAIMONDO ,  Jacobo D SITT ,  Lionel NACCACHE ,  Diego FERNANDEZ SLEZAK

IPC: A61B5/0484 ,  A61B5/00 ,  A61B5/024 ,  A61B5/0205 ,  A61B5/0456 ,  A61B5/0452 ,  A61B5/04

Abstract: Disclosed is a method for the generation of a consciousness indicator for a non-communicating subject, including the steps of generating an auditory stimulation, receiving an electrocardiographic signal of the subject obtained from a recording during the generation of the auditory stimulation, extracting at least one feature from the electrocardiographic signal and deducing a consciousness indicator from an analysis of the electrocardiographic feature.

公开(公告)号：US20200010989A1

公开(公告)日：2020-01-09

申请号：US16492920

申请日：2018-03-09

Applicant: Sorbonne Université ,  Centre National de la Recherche Scientifique

Inventor： Arnaud ANTKOWIAK ,  Paul GRANDGEORGE ,  Natacha KRINS ,  Christel LABERTY-ROBERT

IPC: D04H1/728 ,  D01D5/00 ,  H05K1/02 ,  H05K1/03

Abstract: The present invention relates to a composite membrane (10) comprising a fibrous fabric (1) of nanofibres (11), wherein the thickness of the fabric (1) is between 10 nm and 50 μm and said fabric is impregnated with a wetting liquid (A). According to the invention, the composite membrane is immersed in a second fluid (B) which is immiscible with the wetting liquid (A), forming an A/B interface between the wetting liquid (A) and the immiscible fluid (B), and the composite membrane is capable of remaining tensioned when it is compressed from its resting state until reaching dimensions corresponding to 5% of its dimensions in the resting state, and when it is stretched from its compressed state until reaching dimensions corresponding to 2000% of the length in the compressed state. The present invention also relates to a process for manufacturing such a membrane.

公开(公告)号：US20250127930A1

公开(公告)日：2025-04-24

申请号：US18991814

申请日：2024-12-23

Applicant: GENETHON ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  SORBONNE UNIVERSITÉ ,  UNIVERSITE D'EVRY VAL D'ESSONNE ,  ASSOCIATION INSTITUT DE MYOLOGIE

Inventor： FEDERICO MINGOZZI ,  PASQUALINA COLELLA

IPC: A61K48/00 ,  C12N15/86

Abstract: The present invention relates to hybrid transcription regulatory elements to drive gene expression, in particular hybrid promoters, designed by the fusion of at least two transcription regulatory elements with different tissue selectivity, such as two promoters driving expression in different tissues in a tissue-selective manner.

公开(公告)号：US20250085214A1

公开(公告)日：2025-03-13

申请号：US18292778

申请日：2022-07-29

Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  COLLÈGE DE FRANCE ,  SORBONNE UNIVERSITÉ ,  UNIVERSITÉ DE RENNES 1 ,  ECOLE NATIONALE SUPERIEURE DE CHIMIE DE RENNES ,  INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE RENNES

Inventor： Jean-Marie TARASCON ,  Charlotte GERVILLIE ,  Catherine BOUSSARD ,  Xiang-Hua ZHANG ,  Jean-Luc ADAM

IPC: G01N21/25 ,  G01N21/31 ,  G01N21/35 ,  G01N21/3563 ,  H01M10/48

Abstract: Method for operando characterization of the chemical composition of a battery cell, comprising the following steps: inserting an optical fiber made of chalcogenide glass through the battery cell, cycling the battery, while cycling the battery, generating an optical signal and transmitting it through the optical fiber, detecting, using an infrared spectrometer, the transmitted optical signal at an output extremity of the optical fiber, recording the detected optical signal over time, locating, using fiber evanescent wave spectroscopy, signature wavelengths for which the optical signal intensity is above a predetermined threshold within the spectrum, associating the located signature wavelengths to at least one predetermined chemical species.

公开(公告)号：US20250084069A1

公开(公告)日：2025-03-13

申请号：US18725323

申请日：2023-01-18

Applicant: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  SORBONNE UNIVERSITÉ ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  GREENPHARMA SAS

Inventor： Thierry LEVEILLARD ,  Alexandra Lyor BOUAZIZ ,  Géraldine MILLET-PUEL ,  Franck HIMBERT ,  Philippe BERNARD ,  Jean-Claude BELOEIL

IPC: C07D405/04 ,  A61K31/341 ,  A61K36/185

Abstract: Identification of small organic molecules capable of stimulating aerobic glycolysis and cone survival would lead to the conception of new therapies of the retinal degenerative diseases. Now the inventors identified Geralexin, an acetogenin, extracted from Uvaria chamae a medicinal plant and showed that the molecule can stimulate aerobic glycolysis and cone survival. Geralexin would be suitable for the treatment of retinal degenerative diseases in particular for Age-Related Macular Degeneration (AMD) by preventing cone outer segment shortening and maintaining central vision.

公开(公告)号：US20250051440A1

公开(公告)日：2025-02-13

申请号：US18718492

申请日：2022-12-13

Applicant: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  SORBONNE UNIVERSITÉ ,  UNIVERSITÉ PARIS CITÉ ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)

Inventor： Hafid AIT-OUFELLA ,  Vincent DUVAL

IPC: C07K16/28 ,  A61K39/00 ,  A61K47/68 ,  A61P9/04

Abstract: Myocardial infarction (MI), the most prevalent manifestation of cardiovascular diseases, is associated with high mortality and morbidity. In particular, long term effects of ischemia-related cardiac damage continue to be a clinical and social burden, due to increased risk of arrhythmias, heart failure and repetitive hospitalizations. Therefore, there is a medical need for the development of therapeutic approaches targeting pathophysiological pathways involved in post-ischemic cardiac remodeling. Now, the inventors obtained several evidences confirming that NK cells promote deleterious post-ischemic cardiac remodeling. In particular, the inventors showed that i) NK cells are recruited in the ischemic heart tissue in mouse, ii) NK cells are detected in human ischemic heart tissue, and iii) NK deficiency protects against deleterious post-ischemic cardiac remodeling, and iiii) NK cell depletion using monoclonal antibody in mice protects against deleterious post-ischemic cardiac remodelling and consecutive ischemic heart failure.

公开(公告)号：US12173053B2

公开(公告)日：2024-12-24

申请号：US18337354

申请日：2023-06-19

Applicant: INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Sorbonne Université ,  Assistance Publique-Hôpitaux de Paris (APHP)

Inventor： Guy Gorochov ,  Martin Larsen ,  Delphine Sterlin ,  Jehane Fadlallah

IPC: C07K16/12 ,  A61K9/00 ,  A61K39/00 ,  A61P1/00 ,  A61P37/04

Abstract: The invention is in the field of therapy of antibody deficiencies. Inventors demonstrate for the first time in both controls and IgA-deficient patients. systemic anti-microbiota IgG responses correlate with reduced inflammation suggesting that systemic IgG responses contribute to the gut microbiota confinement. Furthermore. SIgAd-associated inflammation is inversely correlated with systemic anti-commensal IgG responses, which may thus serve as a second line of defense. Altogether, these data suggest that systemic IgG and intestinal IgA cooperate in different body compartments to limit systemic pro-inflammatory pathways. As selective IgA deficient patients harbour elevated seric anti-commensal IgG levels. these findings suggest that in selective IgA deficiency, microbiota confinement is obtained at the price of a strong inflammatory response. Accordingly. the invention relates to a composition containing immunoglobulins A (IgA). more particularly secretory IgA. for use by oral administration in the prevention or treatment of antibody deficiencies such as SIgAd (Selective IgA deficiency) or common variable immunodeficiency (CVID) and associated inflammatory diseases.

公开(公告)号：US12171843B2

公开(公告)日：2024-12-24

申请号：US16968196

申请日：2019-02-07

Applicant: GENETHON ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  SORBONNE UNIVERSITÉ ,  UNIVERSITE D'EVRY VAL D'ESSONNE ,  ASSOCIATION INSTITUT DE MYOLOGIE

Inventor： Federico Mingozzi ,  Pasqualina Colella

IPC: A61K48/00 ,  C12N15/86 ,  C12Q1/68

Abstract: The present invention relates to hybrid transcription regulatory elements to drive gene expression, in particular hybrid promoters, designed by the fusion of at least two transcription regulatory elements with different tissue selectivity, such as two promoters driving expression in different tissues in a tissue-selective manner.

公开(公告)号：US12064181B2

公开(公告)日：2024-08-20

申请号：US16954720

申请日：2017-12-21

Applicant: SORBONNE UNIVERSITÉ ,  ESSILOR INTERNATIONAL

Inventor： José-Alain Sahel ,  Angelo Arleo ,  Anne-Catherine Scherlen ,  Delphine Tranvouez-Bernardin

IPC: A61B3/02 ,  A61B3/00 ,  A61B3/024 ,  A61B3/10 ,  A61B3/113

CPC classification number: A61B3/024 ,  A61B3/0041 ,  A61B3/113

Abstract: A method of analyzing a visual field of an individual comprises the following steps: —measuring (S4) a first visual field (VF1) of said individual for a first set of oculo-postural parameters of said individual when said individual performs a first task; —measuring (S6) at least one additional visual field (VFi) of said individual for one additional set of said oculo-postural parameters of said individual when said individual performs an additional task; —determining (S8) a functional visual space based on said first visual field (VF1) and said at least one additional visual field (VFi), said functional visual space being an envelope of said first visual field and said at least one additional visual field. The additional task differs from said first task and/or said additional set of oculo-postural parameters differs from said first set of oculo-postural parameters. A corresponding ophthalmic lens is also proposed.

公开(公告)号：US20240209069A1

公开(公告)日：2024-06-27

申请号：US18337354

申请日：2023-06-19

Applicant: INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Sorbonne Université ,  Assistance Publique-Hôpitaux de Paris (APHP)

Inventor： Guy GOROCHOV ,  Martin LARSEN ,  Delphine STERLIN ,  Jehane FADLALLAH

IPC: C07K16/12 ,  A61K9/00 ,  A61K39/00 ,  A61P1/00 ,  A61P37/04

CPC classification number: C07K16/1271 ,  A61K9/0053 ,  A61P1/00 ,  A61P37/04 ,  A61K2039/505 ,  A61K2039/542 ,  C07K2317/33

Abstract: The invention is in the field of therapy of antibody deficiencies. Inventors demonstrate for the first time in both controls and IgA-deficient patients. systemic anti-microbiota IgG responses correlate with reduced inflammation suggesting that systemic IgG responses contribute to the gut microbiota confinement. Furthermore. SIgAd-associated inflammation is inversely correlated with systemic anti-commensal IgG responses, which may thus serve as a second line of defense. Altogether, these data suggest that systemic IgG and intestinal IgA cooperate in different body compartments to limit systemic pro-inflammatory pathways. As selective IgA deficient patients harbour elevated seric anti-commensal IgG levels. these findings suggest that in selective IgA deficiency, microbiota confinement is obtained at the price of a strong inflammatory response. Accordingly. the invention relates to a composition containing immunoglobulins A (IgA). more particularly secretory IgA. for use by oral administration in the prevention or treatment of antibody deficiencies such as SIgAd (Selective IgA deficiency) or common variable immunodeficiency (CVID) and associated inflammatory diseases.